High Deviation rates between local and central HER2 assessment and survival with anti-HER2-therapy in advanced Gastric Cancer (GC): Results from the VARIANZ study

F. Lordick; I. Haffner; B. Luber; D. Maier; B. Geier; E. Raimundez; J. Hasenauer; A. Kretzschmar; L. F. von Weikersthal; M. Ahlborn; J. Riera; B. Rau; G. Siegler; S. Fuxius; T. Decker; K. Schierle; C. Wittekind

High Deviation rates between local and central HER2 assessment and survival with anti-HER2-therapy in advanced Gastric Cancer (GC): Results from the VARIANZ study

F. Lordick, I. Haffner, B. Luber, D. Maier, B. Geier, E. Raimundez, J. Hasenauer, A. Kretzschmar, L. F. von Weikersthal, M. Ahlborn, J. Riera, B. Rau, G. Siegler, S. Fuxius, T. Decker, K. Schierle, C. Wittekind

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Original Article › peer-review

Original language	Undefined/Unknown
Journal	Oncology Research and Treatment
Publication status	Published - 2018

Cite this

Lordick, F., Haffner, I., Luber, B., Maier, D., Geier, B., Raimundez, E., Hasenauer, J., Kretzschmar, A., von Weikersthal, L. F., Ahlborn, M., Riera, J., Rau, B., Siegler, G., Fuxius, S., Decker, T., Schierle, K., & Wittekind, C. (2018). High Deviation rates between local and central HER2 assessment and survival with anti-HER2-therapy in advanced Gastric Cancer (GC): Results from the VARIANZ study. Oncology Research and Treatment.

@article{b328ff01e4ce4cc6a158aeb15c4cdb92,

title = "High Deviation rates between local and central HER2 assessment and survival with anti-HER2-therapy in advanced Gastric Cancer (GC): Results from the VARIANZ study",

author = "F. Lordick and I. Haffner and B. Luber and D. Maier and B. Geier and E. Raimundez and J. Hasenauer and A. Kretzschmar and {von Weikersthal}, {L. F.} and M. Ahlborn and J. Riera and B. Rau and G. Siegler and S. Fuxius and T. Decker and K. Schierle and C. Wittekind",

year = "2018",

language = "Undefined/Unknown",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "Karger ",

}

Lordick, F, Haffner, I, Luber, B, Maier, D, Geier, B, Raimundez, E, Hasenauer, J, Kretzschmar, A, von Weikersthal, LF, Ahlborn, M, Riera, J, Rau, B, Siegler, G, Fuxius, S, Decker, T, Schierle, K & Wittekind, C 2018, 'High Deviation rates between local and central HER2 assessment and survival with anti-HER2-therapy in advanced Gastric Cancer (GC): Results from the VARIANZ study', Oncology Research and Treatment.

TY - JOUR

T1 - High Deviation rates between local and central HER2 assessment and survival with anti-HER2-therapy in advanced Gastric Cancer (GC): Results from the VARIANZ study

AU - Lordick, F.

AU - Haffner, I.

AU - Luber, B.

AU - Maier, D.

AU - Geier, B.

AU - Raimundez, E.

AU - Hasenauer, J.

AU - Kretzschmar, A.

AU - von Weikersthal, L. F.

AU - Ahlborn, M.

AU - Riera, J.

AU - Rau, B.

AU - Siegler, G.

AU - Fuxius, S.

AU - Decker, T.

AU - Schierle, K.

AU - Wittekind, C.

PY - 2018

Y1 - 2018

UR - https://publons.com/wos-op/publon/27618471/

M3 - Originalarbeit

SN - 2296-5270

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

ER -

High Deviation rates between local and central HER2 assessment and survival with anti-HER2-therapy in advanced Gastric Cancer (GC): Results from the VARIANZ study

Other files and links

Cite this